{
    "clinical_study": {
        "@rank": "125929", 
        "arm_group": [
            {
                "arm_group_label": "Dapivirine Ring + Miconazole", 
                "arm_group_type": "Active Comparator", 
                "description": "Dapivirine Ring + miconazole"
            }, 
            {
                "arm_group_label": "Dapivirine Ring", 
                "arm_group_type": "Experimental", 
                "description": "Dapivirine Ring"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial will investigate the potential drug-drug interaction between dapivirine vaginal\n      Ring-004 and vaginally administered miconazole nitrate, and will evaluate the safety of\n      co-administration of the dapivirine vaginal ring and miconazole nitrate in healthy,\n      HIV-negative women."
        }, 
        "brief_title": "DDI Potential: Dapivirine Vaginal Ring and Miconazole Nitrate", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "HIV", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Women between 18 and \u2264 40 years of age who can give written informed consent\n\n          2. Available for all visits and consent to follow all procedures scheduled for the trial\n\n          3. Healthy, based on medical history, vital signs, physical examination, urinalysis\n             (dipstick and microscopy (if indicated)), laboratory evaluations for genital\n             infections (bacterial vaginosis, gonorrhoea, chlamydia and trichomonas), and\n             laboratory evaluations for haematology and chemistry\n\n          4. HIV-negative as determined by an HIV test at the time of enrolment\n\n          5. On a stable form of contraception, defined as:\n\n               -  A stable oral contraceptive regimen for at least 2 months prior to enrolment, OR\n\n               -  Transdermal contraceptive patch for at least 3 months prior to enrolment, OR\n\n               -  Long-acting progestins for at least 6 months prior to enrolment, OR\n\n               -  An IUD inserted (with no vaginal or gynaecological complaints associated with\n                  its use) at least 3 months prior to enrolment, OR\n\n               -  Have undergone surgical sterilisation at least 3 months prior to enrolment, AND\n                  willing to use oral contraceptives if necessary to delay menstruation during the\n                  vaginal sampling period\n\n          6. Upon pelvic examination at the time of enrolment, the cervix and vagina appear normal\n             as determined by the Investigator/Physician\n\n          7. Asymptomatic for genital infections at the time of enrolment (if a woman is diagnosed\n             with any treatable STI, either clinically or by laboratory test at the time of\n             screening, she must receive treatment at least 2 weeks prior to enrolment)\n\n          8. Willing to refrain from the use of topical medications, vaginal products or objects,\n             including female condoms, tampons, cotton wool, rags, diaphragms, cervical caps (or\n             any other vaginal barrier method), douches, lubricants, vibrators/dildos, and drying\n             agents for 14 days prior to enrolment and for the duration of the trial.\n\n          9. Documentation of no abnormality on cervical cytology, including grossly bloody smear,\n             within 90 days prior to screening\n\n         10. Willing to refrain from participation in any other research trial for the duration of\n             this trial\n\n         11. Willing to provide adequate locator information for trial retention purposes and be\n             reachable per local standard procedures, e.g. by home visit or telephone, or via\n             family or close neighbour contacts (confidentiality to be maintained)\n\n         12. Willing to agree to abstain from all the following for a total of 2 days (48 hours)\n             prior to each trial visit:\n\n               -  Penile-vaginal intercourse\n\n               -  Oral contact with her genitalia\n\n         13. Hepatitis B and C negative at the time of enrolment.\n\n        Exclusion Criteria:\n\n          1. Currently pregnant or had their last pregnancy outcome within 3 months prior to\n             screening\n\n          2. Currently breast-feeding\n\n          3. Currently or within two months of participation in any other clinical research trial\n             involving investigational or marketed products prior to screening\n\n          4. Untreated symptomatic urogenital infections, e.g. urinary tract or other sexually\n             transmitted infections, or other gynaecological conditions such as vaginal itching,\n             pain, or discharge, within 2 weeks prior to enrolment\n\n          5. Have a Grade 2 or higher pelvic examination finding, according to the DAIDS Table for\n             Grading the Severity of Adult and Pediatric Adverse Events; Addendum 1 Female Genital\n             Grading Table for Use in Microbicide Studies\n\n          6. History of significant urogenital or uterine prolapse, undiagnosed vaginal bleeding,\n             urethral obstruction, incontinence or urge incontinence\n\n          7. Current vulvar or vaginal symptoms/abnormalities that could influence the trial\n             results\n\n          8. Cervical cytology at screening that requires cryotherapy, biopsy, treatment (other\n             than for infection), or further evaluation\n\n          9. Symptomatic genital herpes simplex virus (HSV) infection or a history of genital\n             herpetic infection\n\n         10. Any Grade 2, 3 or 4 haematology, biochemistry or urinalysis laboratory abnormality at\n             baseline (screening) according to the DAIDS Table for Grading the Severity of Adult\n             and Pediatric Adverse Events; Addendum 1 Female Genital Grading Table for Use in\n             Microbicide Studies\n\n         11. Unexplained, abnormal bleeding per vagina during or following vaginal intercourse, or\n             gynaecologic surgery within 90 days prior to enrolment\n\n         12. Any history of anaphylaxis or severe allergy resulting in angioedema; or a history of\n             sensitivity/allergy to latex or silicone\n\n         13. Any serious acute, chronic or progressive disease (e.g. any known history of\n             neoplasm, cancer, diabetes, epilepsy, cardiac disease, autoimmune disease, HIV, AIDS,\n             or blood dyscrasias), or signs of cardiac disease, renal failure, or severe\n             malnutrition\n\n         14. Have undergone a hysterectomy\n\n         15. Any condition(s) that, in the opinion of the Investigator, might interfere with\n             adherence to trial requirements or evaluation of the trial objectives."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01731574", 
            "org_study_id": "IPM 028"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Dapivirine Ring + Miconazole", 
                    "Dapivirine Ring"
                ], 
                "intervention_name": "dapivirine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Dapivirine Ring + Miconazole", 
                "intervention_name": "miconazole", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Miconazole", 
                "Clotrimazole"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "November 6, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Lange Beeldekensstraat 267", 
                    "country": "Belgium", 
                    "state": "Antwerpen", 
                    "zip": "B-2060"
                }, 
                "name": "SGS Life Sciences"
            }
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-label, Randomized, Three-period Crossover Trial in Healthy HIV-negative Women to Assess the Drug-drug Interaction Between Dapivirine Vaginal Ring-004 and Miconazole Nitrate", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "European Union: European Medicines Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Dapivirine Area under the concentration time curve (AUC)", 
            "safety_issue": "No", 
            "time_frame": "24 hr, 14 days, and 28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01731574"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "International Partnership for Microbicides, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "International Partnership for Microbicides, Inc.", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}